Latest News

FDA OKs Suflave, a lower-volume colonoscopy prep drink


 

The Food and Drug Administration has approved Suflave, a new low-volume, lemon-lime flavored liquid osmotic laxative for colonoscopy preparation in adults, the manufacturer, Sebela Pharmaceuticals, has announced.

Suflave comes in a carton containing two bottles and two flavor packets. Each bottle contains 178.7 g polyethylene glycol 3350, 7.3 g sodium sulfate, 1.12 g potassium chloride, 0.9 g magnesium sulfate, and 0.5 g sodium chloride. One bottle and one flavor packet are equivalent to one dose.

Administration of both doses is required for a complete preparation for colonoscopy. After each dose, an additional 16 ounces of water must be consumed.

In a clinical trial, 94% of patients achieved successful bowel cleansing with Suflave, the company said in a news release.

Most patients reported that Suflave tastes like a sports drink and described the taste as “neutral to very pleasant.” Most patients also reported that Suflave was “tolerable to very easy” to consume and indicated they would request it for a subsequent colonoscopy.

“Patients frequently struggle with the taste and volume of traditional bowel preparations – and fear related to the preparation can also negatively affect patient willingness to undergo follow-up colonoscopy if it is indicated,” Douglas K. Rex, MD, gastroenterologist and distinguished professor emeritus at Indiana University, Indianapolis, said in the release.

“I believe the palatable lemon-lime flavor of Suflave will be a welcomed option for patients – reducing preparation hesitancy and giving more people the chance to feel comfortable during preparation and getting a successful and effective procedure,” Dr. Rex added.

Suflave will be available by prescription to patients in the United States in early August.

A version of this article originally appeared on Medscape.com.

Recommended Reading

No link between PPIs and dementia in new study
MDedge Internal Medicine
Should race and ethnicity be used in CRC recurrence risk algorithms?
MDedge Internal Medicine
‘Exciting time for NASH’ with resmetirom phase 3 results
MDedge Internal Medicine
DDW 2023: Common GI conditions in primary care
MDedge Internal Medicine
SAFE algorithm detects liver disease in general population
MDedge Internal Medicine
ADA: Screen all with type 2 diabetes for fatty liver disease
MDedge Internal Medicine
Colorectal cancer: Younger patients fare worse
MDedge Internal Medicine
MRI identifies rectal cancer patients who can skip CRT
MDedge Internal Medicine
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
MDedge Internal Medicine
WHO plans to declare common sweetener as possible carcinogen
MDedge Internal Medicine